Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high‐density lipoprotein (HDL) and triglycerides to apolipoprotein B–containing lipoproteins, especially very low–density lipoproteins (LDL‐C). 1, 2

[1]  P. Gambert,et al.  Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[2]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[3]  Nader Rifai,et al.  Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. , 2002, Clinical chemistry.

[4]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  M. Bamberger,et al.  Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actions⃞ , 2006, Journal of Lipid Research.

[6]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.

[7]  J. Tanne.  Pfizer stops clinical trials of heart drug , 2006, BMJ : British Medical Journal.

[8]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. , 2006, Journal of the American College of Cardiology.

[9]  D. Grobbee,et al.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[10]  C. Shear,et al.  Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[12]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[13]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[14]  Gregory T O'Donnell,et al.  A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. , 2007, Analytical biochemistry.

[15]  John A Wagner,et al.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.

[16]  S. Murdande,et al.  Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. , 2008, International journal of pharmaceutics.

[17]  M. Milad,et al.  Model-based development of gemcabene, a new lipid-altering agent , 2005, The AAPS Journal.

[18]  A. Tall,et al.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.